Publication | Open Access

A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)

Positron Emission TomographyMetastatic Breast CancerBreast OncologyOncologic ImagingBreast ImagingBreast CancerPhase 2EndocrinologyMedicineRadiation OncologyHormone SensitivityNuclear MedicineCancer ResearchEndocrine-related CancerRadiologyHealth Sciences